Jove
Visualize
Contact Us

Related Experiment Videos

Multimodality treatment program in invasive thymic epithelial tumor.

William Jacot1, Xavier Quantin, Sarah Valette

  • 1Service des Maladies Respiratoires, Centre Hospitalier Universitaire de Montpellier, Hôpital Arnaud de Villeneuve, Montpellier, France.

American Journal of Clinical Oncology
|February 3, 2005
PubMed
Summary

Optimal treatment for malignant thymoma and thymic carcinoma remains undefined. A multimodality approach involving neoadjuvant chemotherapy, surgery, and radiotherapy showed limited success in a small case series, highlighting the need for further research.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Determinants of return to work in long-term metastatic breast cancer survivors: Results of a multicenter French cohort.

Bulletin du cancer·2026
Same author

Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study.

Nature communications·2026
Same author

Prognostic value of lymphopenia in early breast cancer: learnings from the prospective CANTO cohort.

Breast cancer research : BCR·2026
Same author

Retrospective Analysis of HER2 Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC With HER2 Mutations in France.

Cancer medicine·2026
Same author

Characteristics, treatment and survival of older patients with metastatic triple negative breast cancer from the ESME mBC real-world national cohort: a comparison with younger women.

Breast (Edinburgh, Scotland)·2026
Same author

Characteristics and outcomes of patients with HER2-negative metastatic breast cancers with low expression of estrogen and progesterone receptors in the multicenter ESME cohort.

Breast (Edinburgh, Scotland)·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Oncology
  • Thoracic Surgery
  • Radiation Oncology

Background:

  • Malignant thymoma and thymic carcinoma are rare thoracic neoplasms with poorly defined optimal treatment strategies.
  • A multimodality approach is often considered to improve patient survival outcomes.
  • Limited data exists on the efficacy of combined neoadjuvant chemotherapy, surgery, and radiotherapy for these conditions.

Purpose of the Study:

  • To report the experience of a single center using a multimodality treatment program for malignant thymoma and thymic carcinoma.
  • To evaluate the feasibility and preliminary outcomes of neoadjuvant chemotherapy, surgery, and postoperative radiotherapy.
  • To identify challenges and potential improvements in managing these rare thymic tumors.

Main Methods:

  • Retrospective review of 8 patients with malignant thymoma or thymic carcinoma treated between December 1995 and June 2001.

Related Experiment Videos

  • Neoadjuvant chemotherapy using the CAP regimen (cyclophosphamide, doxorubicin, cisplatin) followed by surgical resection when feasible.
  • Adjuvant radiotherapy up to 60 Gy for eligible patients, including those who were not surgical candidates.

    • Main Results:

    • Five patients had malignant thymoma and three had thymic carcinoma; five had Masaoka stage IV disease.
    • Partial response to chemotherapy was observed in six patients, with complete resection achieved in two of three surgically treated patients.
    • Four patients completed radiotherapy. Four patients remain alive with no evidence of disease, and one is alive with relapse.

    Conclusions:

    • The observed outcomes were unsatisfactory, potentially due to a high proportion of advanced disease and low treatment compliance.
    • Optimal multimodality treatment strategies for thymic epithelial tumors require further investigation in larger, multicenter trials.
    • Defining standardized treatment protocols is crucial for improving survival in patients with malignant thymoma and thymic carcinoma.